Caveolin-1 ameliorates acetaminophen-aggravated inflammatory damage and lipid deposition in non-alcoholic fatty liver disease via the ROS/TXNIP/NLRP3 pathway

Int Immunopharmacol. 2023 Jan:114:109558. doi: 10.1016/j.intimp.2022.109558. Epub 2022 Dec 21.

Abstract

The overuse of acetaminophen (APAP) may cause more severe hepatotoxicity in patients with non-alcoholic fatty liver disease (NAFLD). Caveolin-1 (CAV1), is an essential regulator of metabolic function, which can alleviate liver damage by scavenging reactive oxygen species (ROS). Evidence suggests that the NOD-like receptor family pyrin domain-containing 3 (NLRP3) -mediated pyroptosis is involved in the development of NAFLD. Moreover, thioredoxin-interactive protein (TXNIP) activation is a key event linking ROS to NLRP3 inflammasome. However, whether CAV1 alleviates APAP-aggravated hepatotoxicity in NAFLD via the ROS/TXNIP/NLRP3 pathway remains unclear. An in vivo fatty liver model was established by feeding mice a high-fat diet for 56 days. Additionally, using in vitro approach, AML-12 cells were incubated with free fatty acids for 48 h and APAP was added during the last 24 h. We found that the overuse of APAP in NAFLD not only induced oxidative stress, but also increased TXNIP expression, NLRP3-mediated pyroptosis, and lipid deposition. In addition to inhibiting ROS generation and lipid deposition, overexpression of CAV1 reduced the elevated levels of TXNIP expression and NLRP3-mediated pyroptosis. However, the effect of CAV1 on TXNIP expression, NLRP3-mediated pyroptosis, and lipid deposition was reversed by CAV1 small interfering RNA (siRNA) intervention. Finally, N-acetyl cysteine (NAC) treatment reduced CAV1 siRNA-mediated changes in TXNIP expression and NLRP3-mediated pyroptosis levels. These results demonstrate that the inhibitory effect of CAV1 on NLRP3-mediated pyroptosis may be mediated through the ROS/TXNIP axis. Moreover, the current study provides novel mechanistic insights into the protective effects of CAV1 on APAP-aggravated hepatotoxicity in NAFLD.

Keywords: Acetaminophen; Caveolin-1; Lipid deposition; Non-alcoholic fatty liver disease; Pyroptosis; ROS/TXNIP/NLRP3.

MeSH terms

  • Acetaminophen
  • Animals
  • Carrier Proteins / genetics
  • Caveolin 1 / metabolism
  • Chemical and Drug Induced Liver Injury* / drug therapy
  • Inflammasomes / metabolism
  • Lipids
  • Mice
  • NLR Family, Pyrin Domain-Containing 3 Protein / metabolism
  • Non-alcoholic Fatty Liver Disease* / drug therapy
  • Non-alcoholic Fatty Liver Disease* / metabolism
  • Pyroptosis
  • RNA, Small Interfering
  • Reactive Oxygen Species / metabolism
  • Thioredoxins / genetics
  • Thioredoxins / metabolism

Substances

  • NLR Family, Pyrin Domain-Containing 3 Protein
  • Acetaminophen
  • Reactive Oxygen Species
  • Caveolin 1
  • Inflammasomes
  • Thioredoxins
  • RNA, Small Interfering
  • Lipids
  • Txnip protein, mouse
  • Carrier Proteins
  • Nlrp3 protein, mouse